Ivana Spasevska

Ivana Spasevska

Auto-generated profile, based on publicly available information

Ivana Spasevska

Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
ISIvana Spasevska
Ivana Spasevska
ASAnkush Sharma
Ankush Sharma
CSChloé B. Steen
Chloé B. Steen
SJSarah E. Josefsson
Sarah E. Josefsson
YBYngvild N. Blaker
Yngvild N. Blaker
JMJune H. Myklebust
June H. Myklebust
Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest substantial heterogeneity in the phenotypes and suppressive capacities of Tregs, emphasizing the importance of understanding Treg diversity and the need for additional markers to identify highly suppressive Tregs. Here, we applied single-cell RNA sequencing and T-cell receptor sequencing combined with high-dimensional cytometry to decipher the heterogeneity of intratumoral Tregs in diffuse large B-cell lymphoma and follicular lymphoma (FL), compared with that in nonmalignant tonsillar tissue. We identified 3 distinct transcriptional states of Tregs: resting, activated, and unconventional LAG3+FOXP3− Tregs. Activated Tregs were enriched in B-NHL tumors, coexpressed several checkpoint receptors, and had stronger immunosuppressive activity compared with resting Tregs. In FL, activated Tregs were found in closer proximity to CD4+ and CD8+ T cells than other cell types. Furthermore, we used a computational approach to develop unique gene signature matrices, which were used to enumerate each Treg subset in cohorts with bulk gene expression data. In 2 independent FL cohorts, activated Tregs was the major subset, and high abundance was associated with adverse outcome. This study demonstrates that Tregs infiltrating B-NHL tumors are transcriptionally and functionally diverse. Highly immunosuppressive activated Tregs were enriched in tumor tissue but absent in the peripheral blood. Our data suggest that a deeper understanding of Treg heterogeneity in B-NHL could open new paths for rational drug design, facilitating selective targeting to improve antitumor immunity.

27 December 2014 in Theoretical Biology and Medical Modelling
Verified
Journal Article
Open access
PDF file
Jack TuszynskiJack Tuszynski
Jack Tuszynski
PWPhilip Winter
Philip Winter
DWDiana White
Diana White
CTChih-Yuan Tseng
Chih-Yuan Tseng
KSKamlesh Sahu
Kamlesh Sahu
RERabab M Abou El-Magd
Rabab M Abou El-Magd
A variety of topics are reviewed in the area of mathematical and computational modeling in biology, covering the range of scales from populations of organisms to electrons in atoms. The use of maximum entropy as an inference tool in the fields of biology and drug discovery is discussed. Mathematical and computational methods and models in the areas of epidemiology, cell physiology and cancer are surveyed. The technique of molecular dynamics is covered, with special attention to force fields for protein simulations and methods for the calculation of solvation free energies. The utility of quantum mechanical methods in biophysical and biochemical modeling is explored. The field of computational enzymology is examined.

Verified
Journal Article
Open access
PDF file
ISIvana Spasevska
Ivana Spasevska
AAAhmed Ayoub
Ahmed Ayoub
PWPhilip Winter
Philip Winter
JPJordane Preto
Jordane Preto
GWGane Ka-Shu Wong
Gane Ka-Shu Wong
Jack TuszynskiJack Tuszynski
Jack Tuszynski
Tubulin is the target for many small-molecule natural compounds, which alter microtubules dynamics, and lead to cell cycle arrest and apoptosis. One of these compounds is colchicine, a plant alkaloid produced by Colchicum autumnale. While C. autumnale produces a potent cytotoxin, colchicine, and expresses its target protein, it is immune to colchicine’s cytotoxic action and the mechanism of this resistance is hitherto unknown. In the present paper, the molecular mechanisms responsible for colchicine resistance in C. autumnale are investigated and compared to human tubulin. To this end, homology models for C. autumnale α-β tubulin heterodimer are created and molecular dynamics (MD) simulations together with molecular mechanics Poisson–Boltzmann calculations (MM/PBSA) are performed to determine colchicine’s binding affinity for tubulin. Using our molecular approach, it is shown that the colchicine-binding site in C. autumnale tubulin contains a small number of amino acid substitutions compared to human tubulin. However, these substitutions induce significant reduction in the binding affinity for tubulin, and subsequently fewer conformational changes in its structure result. It is suggested that such small conformational changes are insufficient to profoundly disrupt microtubule dynamics, which explains the high resistance to colchicine by C. autumnale.

17 April 2024 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
LMLeo Meriranta
Leo Meriranta
SSSelma Sorri
Selma Sorri
KHKanutte Huse
Kanutte Huse
XLXiaonan Liu
Xiaonan Liu
ISIvana Spasevska
Ivana Spasevska
SLSirpa Leppä
Sirpa Leppä
Pathomechanisms that activate oncogenic B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma (DLBCL) are largely unknown. Kelch-like family member 6 (KLHL6) encoding a substrate-adapter for Cullin-3-RING E3 ubiquitin ligase with poorly established targets is recurrently mutated in DLBCL. By applying high-throughput protein interactome screens and functional characterization, we discovered that KLHL6 regulates BCR by targeting its signaling subunits CD79A and CD79B. Loss of physiologic KLHL6 expression pattern was frequent among the MCD/C5-like activated B-cell DLBCLs and was associated with higher CD79B levels and dismal outcome. Mutations in the bric-a-brac tramtrack broad domain of KLHL6 disrupted its localization and heterodimerization and increased surface BCR levels and signaling, whereas Kelch domain mutants had the opposite effect. Malfunctions of KLHL6 mutants extended beyond proximal BCR signaling with distinct phenotypes from KLHL6 silencing. Collectively, our findings uncover how recurrent mutations in KLHL6 alter BCR signaling and induce actionable phenotypic characteristics in DLBCL. Significance: Oncogenic BCR signaling sustains DLBCL cells. We discovered that Cullin-3-RING E3 ubiquitin ligase substrate-adapter KLHL6 targets BCR heterodimer (CD79A/CD79B) for ubiquitin-mediated degradation. Recurrent somatic mutations in the KLHL6 gene cause corrupt BCR signaling by disrupting surface BCR homeostasis. Loss of KLHL6 expression and mutant-induced phenotypes associate with targetable disease characteristics in B-cell lymphoma. See related commentary by Leveille et al. See related commentary by Corcoran et al.

1 November 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
ISIvana Spasevska
Ivana Spasevska
EMEva Laure Matera
Eva Laure Matera
KCKamel Chettab
Kamel Chettab
JVJade Ville
Jade Ville
MPMarie Potier-Cartereau
Marie Potier-Cartereau
CDCharles Dumontet
Charles Dumontet
Direct cell death induction, in addition to immune-effector cell-mediated mechanisms, is one of the key mechanisms of action of anti-CD20 antibodies, and yet the signaling pathways implicated remain poorly investigated. Here we show that the transcription factor EGR-1 is rapidly induced by anti-CD20 antibodies and is a key mediator for CD20-induced cell death. EGR-1 induction results from an increased calcium influx induced by anti-CD20 antibodies. We show that both rituximab and obinutuzumab induce calcium influx, albeit through different mechanisms, and this influx is crucial for cell death induction. Inhibition of the calcium flux with calcium channel blockers (CCB) abolished EGR-1 induction and impaired the efficacy of anti-CD20 antibodies in preclinical in vitro and in vivo models. Finally, we investigated the impact of CCBs in patients treated with anti-CD20 antibodies included in the clinical trials GOYA and REMARC, and found that patients simultaneously receiving CCBs and anti-CD20 therapy have a shorter progression-free survival and overall survival. These results reveal EGR-1 as a key mediator of the direct cytotoxic activity of anti-CD20 antibodies and provide a rationale to evaluate EGR-1 expression as a new biomarker to predict response to anti-CD20 treatment. In addition, our findings show that calcium influx is required for anti-CD20–mediated tumor cell death and suggest that simultaneous administration of calcium channel blocking agents could be deleterious in patients receiving anti-CD20–based immunotherapy.

17 June 2026
Verified
Other
Open access
LMLeo Meriranta
Leo Meriranta
SSSelma Sorri
Selma Sorri
KHKanutte Huse
Kanutte Huse
XLXiaonan Liu
Xiaonan Liu
ISIvana Spasevska
Ivana Spasevska
SLSirpa Leppä
Sirpa Leppä
Figure S1 shows KLHL6 expression and its molecular correlates in reactive lymphoid and DLBCL tissues. Figure S2 shows recurrent KLHL6 mutations and their subcellular localization. Figure S3 shows data from affinity-purification mass-spectrometry (AP-MS) interactome analysis of Strep-tagged wild-type KLHL6 in the expansion cell line panel. Figure S4 shows data related to proximity-labeling interactome analysis of KLHL6. Figure S5 shows KLHL6 interactome upon BCR stimulation and the impact of recurrent mutations on BCR levels. Figure S6 shows the impact of KLHL6 constructs on the surface levels expression of the BCR components. Figure S7 shows the impact of KLHL6 constructs on the BCR signaling. Figure S8 shows immunofluorescent analysis and quantification of CD79B staining intensity. Figure S9 shows BANK1 expression in DLBCL.